Cargando…

Safety of antimicrobial de-escalation for culture-negative severe pneumonia

PURPOSE: This study investigated the outcomes of antimicrobial de-escalation (ADE) based on mortality and the incidence of multi-drug resistant (MDR) pathogen occurrence in patients with culture-negative pneumonia presenting with sepsis and septic shock. MATERIALS AND METHODS: We retrospectively ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Byoung Soo, Kwon, Sang Ho, Choi, Younsuck, Koh, Jin-Won, Huh, Sang-Bum, Hong, Chae-Man, Lim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126337/
https://www.ncbi.nlm.nih.gov/pubmed/31319347
http://dx.doi.org/10.1016/j.jcrc.2019.06.026
_version_ 1783516125369204736
author Byoung Soo, Kwon
Sang Ho, Choi
Younsuck, Koh
Jin-Won, Huh
Sang-Bum, Hong
Chae-Man, Lim
author_facet Byoung Soo, Kwon
Sang Ho, Choi
Younsuck, Koh
Jin-Won, Huh
Sang-Bum, Hong
Chae-Man, Lim
author_sort Byoung Soo, Kwon
collection PubMed
description PURPOSE: This study investigated the outcomes of antimicrobial de-escalation (ADE) based on mortality and the incidence of multi-drug resistant (MDR) pathogen occurrence in patients with culture-negative pneumonia presenting with sepsis and septic shock. MATERIALS AND METHODS: We retrospectively analyzed patients diagnosed with severe pneumonia requiring intensive care unit (ICU) admission and possessing negative microbiological culture results at a tertiary referral hospital in South Korea from March 2008 to July 2018. RESULTS: We identified 107 patients with culture-negative pneumonia. The Acute Physiologic and Chronic Health Evaluation (APACHE) II and Sepsis-related Organ Failure Assessment (SOFA) mean scores were 20.3 ± 8.6 and 9.6 ± 3.3, respectively. Among the patients, 40 (37.4%) underwent ADE. The APACHE II, SOFA, and follow-up SOFA scores did not differ significantly between the groups, and no differences were found in ICU mortality and MDR pathogen occurrence (27.5% vs 41.8%, P = .137 and 15.0% vs 16.9% P = .794, respectively). CONCLUSIONS: We observed similar ICU mortality and MDR pathogen occurrence in patients with culture-negative pneumonia presenting with sepsis/shock regardless of whether they received ADE. Additionally, ADE lowered the antimicrobial burden.
format Online
Article
Text
id pubmed-7126337
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71263372020-04-08 Safety of antimicrobial de-escalation for culture-negative severe pneumonia Byoung Soo, Kwon Sang Ho, Choi Younsuck, Koh Jin-Won, Huh Sang-Bum, Hong Chae-Man, Lim J Crit Care Article PURPOSE: This study investigated the outcomes of antimicrobial de-escalation (ADE) based on mortality and the incidence of multi-drug resistant (MDR) pathogen occurrence in patients with culture-negative pneumonia presenting with sepsis and septic shock. MATERIALS AND METHODS: We retrospectively analyzed patients diagnosed with severe pneumonia requiring intensive care unit (ICU) admission and possessing negative microbiological culture results at a tertiary referral hospital in South Korea from March 2008 to July 2018. RESULTS: We identified 107 patients with culture-negative pneumonia. The Acute Physiologic and Chronic Health Evaluation (APACHE) II and Sepsis-related Organ Failure Assessment (SOFA) mean scores were 20.3 ± 8.6 and 9.6 ± 3.3, respectively. Among the patients, 40 (37.4%) underwent ADE. The APACHE II, SOFA, and follow-up SOFA scores did not differ significantly between the groups, and no differences were found in ICU mortality and MDR pathogen occurrence (27.5% vs 41.8%, P = .137 and 15.0% vs 16.9% P = .794, respectively). CONCLUSIONS: We observed similar ICU mortality and MDR pathogen occurrence in patients with culture-negative pneumonia presenting with sepsis/shock regardless of whether they received ADE. Additionally, ADE lowered the antimicrobial burden. Elsevier Inc. 2019-12 2019-06-28 /pmc/articles/PMC7126337/ /pubmed/31319347 http://dx.doi.org/10.1016/j.jcrc.2019.06.026 Text en © 2019 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Byoung Soo, Kwon
Sang Ho, Choi
Younsuck, Koh
Jin-Won, Huh
Sang-Bum, Hong
Chae-Man, Lim
Safety of antimicrobial de-escalation for culture-negative severe pneumonia
title Safety of antimicrobial de-escalation for culture-negative severe pneumonia
title_full Safety of antimicrobial de-escalation for culture-negative severe pneumonia
title_fullStr Safety of antimicrobial de-escalation for culture-negative severe pneumonia
title_full_unstemmed Safety of antimicrobial de-escalation for culture-negative severe pneumonia
title_short Safety of antimicrobial de-escalation for culture-negative severe pneumonia
title_sort safety of antimicrobial de-escalation for culture-negative severe pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126337/
https://www.ncbi.nlm.nih.gov/pubmed/31319347
http://dx.doi.org/10.1016/j.jcrc.2019.06.026
work_keys_str_mv AT byoungsookwon safetyofantimicrobialdeescalationforculturenegativeseverepneumonia
AT sanghochoi safetyofantimicrobialdeescalationforculturenegativeseverepneumonia
AT younsuckkoh safetyofantimicrobialdeescalationforculturenegativeseverepneumonia
AT jinwonhuh safetyofantimicrobialdeescalationforculturenegativeseverepneumonia
AT sangbumhong safetyofantimicrobialdeescalationforculturenegativeseverepneumonia
AT chaemanlim safetyofantimicrobialdeescalationforculturenegativeseverepneumonia